98021-79-5

Basic information

• Product Name: 3-BroModihydro-2H-pyran-4(3H)-one
• Synonyms: 3-BroModihydro-2H-pyran-4(3H)-one;3-BroModihydro-2H-pyran-4...;3-Bromotetrahydro-4H-pyran-4-one;3-BroMotetrahydropyran-4-one;3-bromooxan-4-one
• CAS NO: 98021-79-5
• Molecular Formula: C₅H₇BrO₂
• Molecular Weight: 179.01188
• Mol File: 98021-79-5.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 226.5±35.0℃ (760 Torr)
• Flash Point: 90.8±25.9℃
• Appearance: /Solid
• Density: 1.652±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.082mmHg at 25°C
• Refractive Index: 1.513
• CAS DataBase Reference: 3-BroModihydro-2H-pyran-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BroModihydro-2H-pyran-4(3H)-one(98021-79-5)
• EPA Substance Registry System: 3-BroModihydro-2H-pyran-4(3H)-one(98021-79-5)

Safety Data

• RIDADR: UN1760
• Hazardous Substances Data: 98021-79-5(Hazardous Substances Data)

Usage

General Description

3-Bromodihydro-2H-pyran-4(3H)-one is a chemical compound that belongs to the class of heterocyclic compounds. It is a cyclic organic compound containing a pyran ring, which is a six-membered heterocyclic ring with five carbon atoms and one oxygen atom. The presence of a bromine atom and a dihydro-2H-pyran-4(3H)-one moiety in the structure of this compound gives it unique chemical and physical properties. It may be used in organic synthesis, pharmaceutical research, and other industrial applications due to its potential reactivity and structural characteristics. Further research and testing may be required to fully understand the applications and potential hazards of this compound.

InChI:InChI=1/C5H7BrO2/c6-4-3-8-2-1-5(4)7/h4H,1-3H2

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 84302-42-1 2,3-dihydro-4H-pyran-4-one 
• 108-97-4 4-pyrone 
• 56-23-5 tetrachloromethane 
• 128-08-5 N-Bromosuccinimide 
• 52215-12-0 pyrrolidone hydrotribromide 

Downstream Products

• 1263868-85-4 3-(4-fluorophenyl)-dihydro-2H-pyran-4(3H)-one 
• 1263868-86-5 8-(4-fluorophenyl)-7,8-dihydropyrano[3,4-e][1,3]oxazine-2,4(3H,5H)-dione 
• 1263868-87-6 8-(4-fluorophenyl)-7,8-dihydro-1H-pyrano[4,3-d]pyrimidine-2,4(3H,5H)-dione 
• 1263868-84-3 2,4-dichloro-8-(4-fluorophenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 
• 1263868-88-7 2-chloro-8-(4-fluorophenyl)-N-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine 
• 1263868-89-8 2-chloro-N-ethyl-8-(4-fluorophenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine 
• 1263871-67-5 2-chloro-8-((S)-4-fluorophenyl)-4-((R)-3-fluoropyrrolidin-1-yl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 
• 1263871-68-6 2-chloro-8-((S)-4-fluorophenyl)-4-((S)-3-fluoropyrrolidin-1-yl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 
• 1263868-92-3 2-chloro-8-(4-fluorophenyl)-N,N-dimethyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine 
• 1263868-93-4 2-chloro-N-ethyl-8-(4-fluorophenyl)-N-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine 
• 1263868-94-5 2-chloro-4-(3,3-difluoroazetidin-1-yl)-8-(4-fluorophenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 
• 1068523-26-1 1,4,8-trioxaspiro[4.5]decan-6-amine 
• 259810-12-3 2-amino-6,7-dihydro-4H-pyrano[4,3-d]-thiazole 
• 1443103-49-8 (±)-3-bromo-N-(4-methoxybenzyl)tetrahydro-2H-pyran-4-amine 

Relevant articles and documents

6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS

The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected β-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration.

CYCLIC UREA DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS

The present invention is directed to compounds of formula (I) wherein R1, R2, R3, and A are defined herein. The present invention also provides for pharmaceutical compositions comprising a compound of formula (I) as well as to the use of such compounds as androgen receptor antagonists for the treatment of diseases and conditions mediated by the androgen receptor, such as prostate cancer.